Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PRNP | P04156 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NR0B1 | P51843 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brefeldin A SCHEMBL30460472 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL17167480 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL30460466 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL12648486 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL29268 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL13073124 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL4967944 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL4345242 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL8264765 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP | |
| Brefeldin A SCHEMBL26040278 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20080241194-A1 | COMPOSITIONS AND METHODS FOR PROTECTING ORGANS, TISSUE AND CELLS FROM IMMUNE SYSTEM-MEDIATED DAMAGE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1107789-B1 | COMPOSITIONS AND METHODS FOR PROTECTING ORGANS, TISSUE AND CELLS FROM IMMUNE SYSTEM-MEDIATED DAMAGE | UNIV LELAND STANFORD JUNIOR (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0831807-B1 | USE OF BREFELDIN A AND DERIVATIVES THEREOF IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF HYPERPLASIA AND RELATED DISORDERS | ZYMOGENETICS INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040191253-A1 | Inhibition of intimal hyperplasia using antibodies to PDGF receptors | HART CHARLES E (US) | 2004-09-30 | — | — | US | disclosed |
| EP-0801572-B1 | COMPOSITION FOR INHIBITING INTIMAL HYPERPLASIA USING PDGF ANTAGONISTS AND HEPARIN | ZYMOGENETICS INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20020044933-A1 | Inhibition of intimal hyperplasia using antibodies to PDGF receptors | ZYMOGENETICS, INC. | 2002-04-18 | — | — | US | disclosed |
| US-5976534-A | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin | ZYMOGENETICS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0679627-B1 | Process for the preparation of halogenated ethers | SCHWEIZERHALL SAEUREFAB (CH) | 1998-09-09 | — | — | EP | disclosed |
| EP-0801572-A2 | COMPOSITION FOR INHIBITING INTIMAL HYPERPLASIA USING PDGF ANTAGONISTS AND HEPARIN | ZymoGenetics, Inc. (US) | 1997-10-22 | — | — | EP | disclosed |
| US-5637775-A | REACTING ACETAL WITH HYDROGEN CHLORIDE OR BROMIDE OR THIONYL CHLORIDE OR BROMIDE, IN LATTER CASE IN PRESENCE OF N,N-DILOWERALKYL-LOWERALKANOYLAMIDE CATALYST, DISTILLING | SAUREFABRIK SCHWEIZERHALL (CH) | 1997-06-10 | — | — | US | disclosed |
| US-5618837-A | PDGF antagonists III | ZYMOGENETICS, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1996020718-A2 | COMPOSITION FOR INHIBITING INTIMAL HYPERPLASIA USING PDGF ANTAGONISTS AND HEPARIN | ZYMOGENETICS, INC. (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0679627-A1 | Process for the preparation of halogenated ethers | Säurefabrik Schweizerhall (CH) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191253-A1 | Inhibition of intimal hyperplasia using antibodies to PDGF receptors | PDGFA, PDGFRB, PDGFRA | NPC1 4619/4885RAB9A 3815/4885LMNA 3750/4885 |
| US-20020044933-A1 | Inhibition of intimal hyperplasia using antibodies to PDGF receptors | PDGFA, PDGFRB, PDGFRA | NPC1 4619/4885RAB9A 3815/4885LMNA 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.